论文部分内容阅读
罗格列酮(Avandia)是一种噻唑烷二酮类口服降糖药,主要通过增加肌肉和脂肪组织的胰岛素敏感性和抑制肝糖元异生来调控血糖。该药于2000年3月在加拿大上市。单用罗格列酮的临床试验发现该药可增加总胆固醇、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平而降低游离脂肪酸水平。在罗格列酮临床试验中,1400名以上的患者未发现有HDL-C水平下降。值得注意的是,氯贝特对HDL-C和甘油三酯有益,偶尔会出现HDL-C和载脂蛋白A-Ⅰ的降低。
Avandia is an oral hypoglycemic agent of thiazolidinediones that regulates blood glucose mainly by increasing insulin sensitivity in muscle and adipose tissue and by inhibiting hepatic gluconeogenesis. The drug was marketed in Canada in March 2000. Clinical trials with rosiglitazone alone have found that the drug reduces free fatty acid levels by increasing levels of total cholesterol, low density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). In rosiglitazone clinical trials, no increase in HDL-C levels was observed in more than 1,400 patients. Of note, clofibrate is beneficial for HDL-C and triglycerides, with occasional reductions in HDL-C and apolipoprotein A-I.